Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Industri Jamu dan Farmasi Sido Muncul Tbk's quarterly Accounts Payable
increased
from Sep. 2025 (Rp116,838 Mil) to Dec. 2025 (Rp211,524 Mil) but then
declined
from Dec. 2025 (Rp211,524 Mil) to Mar. 2026 (Rp150,137 Mil).
PT Industri Jamu dan Farmasi Sido Muncul Tbk's annual Accounts Payable
declined
from Dec. 2023 (Rp187,198 Mil) to Dec. 2024 (Rp177,031 Mil) but then
increased
from Dec. 2024 (Rp177,031 Mil) to Dec. 2025 (Rp211,524 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Industri Jamu dan Farmasi Sido Muncul Tbk Accounts Payable Chart
PT Industri Jamu dan Farmasi Sido Muncul Tbk Annual Data
PT Industri Jamu dan Farmasi Sido Muncul Tbk Accounts Payable Calculation
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
What does a Accounts Payable of Rp150,137 Mil mean?
PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) has a Accounts Payable of Rp150,137 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on PT Industri Jamu dan Farmasi Sido Muncul Tbk and its competitors.
Is PT Industri Jamu dan Farmasi Sido Muncul Tbk's Accounts Payable too high?
PT Industri Jamu dan Farmasi Sido Muncul Tbk's current Accounts Payable is Rp150,137 Mil. Overall, PT Industri Jamu dan Farmasi Sido Muncul Tbk has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Industri Jamu dan Farmasi Sido Muncul Tbk's Accounts Payable compare to KHC and GIS?
PT Industri Jamu dan Farmasi Sido Muncul Tbk's Accounts Payable of Rp150,137 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Consumer Packaged Goods company?
A good Accounts Payable depends on the Consumer Packaged Goods industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on PT Industri Jamu dan Farmasi Sido Muncul Tbk and its competitors. PT Industri Jamu dan Farmasi Sido Muncul Tbk's current Accounts Payable is Rp150,137 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Industri Jamu dan Farmasi Sido Muncul Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp611.18, compared to a current price of Rp356.00 — trading 41.8% below its estimated fair value. The current Accounts Payable is Rp150,137 Mil. PT Industri Jamu dan Farmasi Sido Muncul Tbk's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO), the current Accounts Payable is Rp150,137 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) Overvalued in 2026?
Based on GuruFocus' analysis, PT Industri Jamu dan Farmasi Sido Muncul Tbk stock appears to be undervalued.
The current stock price of Rp356.00 is trading 41.8% below its estimated GF Value™ of Rp611.18.
GuruFocus considers PT Industri Jamu dan Farmasi Sido Muncul Tbk to be Significantly Undervalued.
Key valuation signals for ISX:SIDO:
Accounts Payable: Rp150,137 Mil
GF Value™: Rp611.18 vs. price of Rp356.00 (41.8% below fair value)
No single metric tells the full story. See the ISX:SIDO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Industri Jamu dan Farmasi Sido Muncul Tbk is focused on the herbal medicine and herbal products industry, with its products categorized into three distinct segments: Herbal Medicine and Supplements, Food and Beverages, and Pharmaceuticals. Its flagship herbal products include Tolak Angin, available in variants such as Tolak Angin Cair, Tolak Angin Cair Anak, Tolak Angin Sugar Free, Tolak Angin Batuk, and Tolak Angin Flu. The Herbal Medicine segment provides herbal supplements, while its Food and Beverage segment sells packaged foods, soft drinks, and candy and confectionery products. The Pharmacy segment sells pharmaceutical products, including Anacetine Syrup, Inflasone, Berlosid, Licokalk, and Licodexon. The majority of revenue is derived from the Herbal Medicine & Supplement segment.
84GF Score
Get the complete analysis for ISX:SIDO
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SIDO has been successfully added to your 
